Skip to main content
SpringerLink
Log in

Interferon treatment of chronic hepatitis B surface antigen (HBsAg) carriers. A description of the activation profiles of natural killer cells obtained with different schedules of administration in three subsets of carriers

  • Original Contributions
  • Published:
Ricerca in clinica e in laboratorio

Summary

By monitoring immunobiological parameters known to be influenced by interferon (IFN), the natural killer (NK) cell activity of 10 low replication (anti-HBe) virus B-DNA (HBV-DNA) hepatitis patients receiving rIFN α-A, of 5 anti-HBe/δ positive hepatitis patients treated with rIFN α-2, and of 6 high replication (HBeAg) HBV-DNA hepatitis patients on lymphoblastoid IFN was followed-up during therapy. Overall, strong and significant (p<0.01) shift to increase segregated with the low replication subset; the δ positive subset was non-significantly increased (0.30>p>0.2); the high replication subset was depressed in a nearly significant (0.10>p>0.05) manner. Kinetic studies showed the activation of the first subset to follow an early steep rise and a subsequent plateau as fitted with a quadratic curve (p=0.02); an early rise and a depression at 2 months delineated a complex cubic model (p=0.06) in the high replication subset. The profound NK depression was clinically witnessed by a sharp rise of the aminotransferases and following drop of viremia. The study shows thati. discrete patterns of NK response as amenable to mathematical models may associate to differential patterns of virus B replication in patients responding to IFN;ii. point(s) on the NK curve may acquire clinical meaning as they coincide with a consensual or opposite shift of a clinical index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. BMDP Statistical Software. University of California Press, Los Angeles, 1981. BMDP2V, p. 359.

  2. Bonino F., Rosina F., Rizzetto M., Rizzi R., Chiaberge E., Tardanico R., Callea F., Verme G.: Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe — Gastroenterology90, 1268, 1986.

    PubMed  CAS  Google Scholar 

  3. Bukovski J. F., Woda B. A., Habu S., Okumura K., Welsh R.: NK depletion enhances virus synthesis and virus-induced hepatitisin vivo — J. Immunol.131, 1531, 1983.

    Google Scholar 

  4. Czaja A. J.: Natural history of chronic active hepatitis. In:Czaja A. J., Dickson E. R. (Eds): Chronic active hepatitis (the Mayo Clinic experience). M. Dekker, New York, 1986; p. 9.

    Google Scholar 

  5. Dooley J. S., Davis G. L., Peters M., Waggoner J. G., Goodman Z., Hoofnagle J. H.: Pilot study of recombinant human α-interferon for chronic type B hepatitis — Gastroenterology90, 150, 1986.

    PubMed  CAS  Google Scholar 

  6. Dusheiko G. M., Dibisceglie A., Bowyer S., Sacks F., Kew M. C.: Prolonged recombinant leukocyte α-IFN treatment of chronic hepatitis B — Hepatology4, 158, 1984.

    Google Scholar 

  7. Ikeda T., Lever A., Thomas H. C.: Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life — Hepatology6, 962, 1986.

    Article  PubMed  CAS  Google Scholar 

  8. Lotzova E., Savary C. A., Gutterman J. U., Hersh E. M.: Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned IFN-α — Cancer Res.42, 2480, 1982.

    PubMed  CAS  Google Scholar 

  9. Maluish A. E., Ortaldo J. R., Sherwin S.: Depression of NK cytotoxicity afterin vivo administration of recombinant leukocyte interferon — J. Immunol.131, 503, 1983.

    PubMed  CAS  Google Scholar 

  10. Martz G.: Editorial — Advanc. therapeut. Commun.1, 5, 1985.

    Google Scholar 

  11. Matsumara N., Yoshikawa T., Kondo M., Imanishi J., Kishida T.: Effect of low dosage of IFN on NK activity in patients with HBsAg-positive chronic active hepatitis — Digestion30, 195, 1984.

    Article  Google Scholar 

  12. Neefe J. R., Sullivan J. E., Ayoob M., Phillips E., Smith F. P.: Augmented immunity in cancer patients treated with α-interferon — Cancer Res.45, 874, 1985.

    PubMed  CAS  Google Scholar 

  13. Negro F., Chiaberge E., Olivero S., Hammer M., Berninger M., Canese M. G., Bonino F.: Hepatitis B virus DNA in anti-HBe positive sera — Liver4, 177, 1984.

    PubMed  CAS  Google Scholar 

  14. Omata M., Imazeki F., Yokoshuka O., Ito Y., Uchiumi K., Mori J., Okuda K.: Recombinant leukocyte α-interferon treatment in patients with chronic hepatitis B virus infection — Gastroenterology88, 870, 1985.

    PubMed  CAS  Google Scholar 

  15. Ortaldo J. R., Bonnard G. D., Herberman R. B.: Cytotoxic reactivity of human lymphocytes culturedin vitro — J. Immunol.119, 13, 1977.

    Google Scholar 

  16. Pignatelli M., Waters J., Brown D.: HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection — Hepatology6, 349, 1986.

    Article  PubMed  CAS  Google Scholar 

  17. Rizzetto M., Shih J. W. K., Gerin J. L.: The hepatitis B virus-associated delta antigen (delta); isolation from liver, development of a solid-phase radioimmunoassay for delta/anti-delta, and partial characterization of delta — J. Immunol.125, 318, 1980.

    PubMed  CAS  Google Scholar 

  18. Rizzetto M., Verme G., Recchia S., Bonino F., Farci P., Aricò S., Calzia R., Picciotto A., Colombo M., Popper H.: Chronic HBsAg hepatitis with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment — Ann. intern. Med.98, 437, 1983.

    PubMed  CAS  Google Scholar 

  19. Sanchez-Tapias J. M., Vilar J. H., Costa J., Bruguera M., Ballesta A. M., Rodes J.: Natural history of chronic persistent hepatitis B. Relationship between hepatitis B virus replication and the course of the disease — J. Hepatol.1, 15, 1984.

    Article  Google Scholar 

  20. Scully L. J., Brown D., Lloyd C., Shein R., Thomas H. C.: Immunologic studies before and during IFN therapy in chronic HBV infection: identification of factors predicting response — J. Hepatol. 1987. (In press).

  21. Scully L. J., Shein R., Lok A. S. F., Karayiannis P., Thomas H. C.: Lymphoblastoid IFN therapy of chronic hepatitis B virus infection. Different racial response — J. Hepatol.2, 5329, 1965. (Abstract).

    Google Scholar 

  22. Smedile A., Rizzetto M., Denniston K., Bonino F., Wells F., Verme G., Consolo F., Hoyer B., Purcell R. H., Gerin J. L.: Type D hepatitis: the clinical significance of hepatitis D virus RNA in serum as detected by a hybridization based assay — Hepatology6, 1297, 1986.

    Article  PubMed  CAS  Google Scholar 

  23. Spina C. A., Fahey J. L., Durkos Smith D., Dorey F., Sarna G.: Suppression of NK cell cytotoxicity in peripheral blood of patients receiving interferon therapy — J. biol. Res. Modif.2, 450, 1983.

    Google Scholar 

  24. Warren H. S.: The generation of specific cytotoxic responses by human lymphocytes requires antigen and activities provided by a lymphokine supernatant — Scand. J. Immunol.14, 71, 1981.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Gastroenterologia, Ospedale Molinette, Corso Bramante 88, 10126, Torino, Italia

    Giovanni Clemente Actis, Eleonora Maran, Giorgio Saracco, Floriano Rosina, Maurizia Rossana Brunetto, Maurizio Baldi, Valter Lattore, Ferruccio Bonino, Mario Rizzetto & Giorgio Verme

  2. Centro di Biostatistica, Ospedale Molinette, Torino

    Giuseppe Rocca

Authors
  1. Giovanni Clemente Actis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleonora Maran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgio Saracco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Floriano Rosina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maurizia Rossana Brunetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maurizio Baldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valter Lattore
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giuseppe Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ferruccio Bonino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mario Rizzetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Giorgio Verme
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Actis, G.C., Maran, E., Saracco, G. et al. Interferon treatment of chronic hepatitis B surface antigen (HBsAg) carriers. A description of the activation profiles of natural killer cells obtained with different schedules of administration in three subsets of carriers. La Ricerca Clin. Lab. 17, 331–341 (1987). https://doi.org/10.1007/BF02886916

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02886916

Key-words

Search

Navigation